Caliway advances CBL-514: 69.60 percent response matters for Caliway Biopharmaceuticals stock
Published on 10/22/2026 at 12:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical program moves toward testing
- CBL-514 produced a 69.60 percent response on October 21, 2026.
- First-half 2026 revenue reached TWD 3.568 million while net loss narrowed to TWD 330.270 million.
- Caliway Biopharmaceuticals stock was last at TWD 73.80 on October 22, 2026 at 1:30 p.m. CST.
Caliway Biopharmaceuticals C (ISIN TW0006919004) is advancing CBL-514 toward phase 3 after 69.60 percent of treated participants achieved at least 150 milliliters of subcutaneous fat reduction at eight weeks, Pharmaphorum reported on October 21, 2026. The result gives the company a clinical bridge from phase 2 data to two planned placebo-controlled phase 3 trials.
CBL-514 enters a larger test
The data set points to a mechanism distinct from appetite-focused incretin drugs. Visceral fat fell 12.00 percent with CBL-514, while it increased 5.68 percent with placebo, according to Pharmaphorum on October 21, 2026. The planned phase 3 program will test large-area abdominal subcutaneous fat reduction in a controlled setting.
What do the finances show?
The clinical advance comes alongside a small commercial base. In the first half of 2026, revenue was TWD 3.568 million versus TWD 12.212 million in the prior-year period, while net loss narrowed to TWD 330.270 million from TWD 424.378 million, Quartr reported on October 7, 2026. Operating expenses rose to TWD 511.244 million from TWD 393.249 million, leaving development progress dependent on continued funding.
Three dated developments
On October 7, 2026, the first-half report showed TWD 3.568 million in revenue and a TWD 330.270 million net loss, according to Quartr. On October 19, 2026, Caliway's Taiwan-listed stock closed at TWD 75.90, according to Global Banking and Finance Review. On October 21, 2026, Pharmaphorum reported the 69.60 percent CBL-514 response and the move toward phase 3 trials.
Market value and trading level
Caliway's market capitalization was TWD 114.9 billion as of October 22, 2026. Its 52-week range was TWD 73.80 to TWD 188.00, placing the latest quote at the bottom of that interval. Caliway was last at TWD 73.80 on the Taiwan Stock Exchange on October 22, 2026 at 1:30 p.m. CST.
Caliway Biopharmaceuticals stock facts
- Company: Caliway Biopharmaceuticals Co., Ltd.
- ISIN: TW0006919004
- Ticker: 6919
- Primary exchange: Taiwan Stock Exchange
- Price Taiwan Stock Exchange: TWD 73.80 (as of October 22, 2026, 1:30 p.m. CST)
- Market capitalization: TWD 114.9 billion (as of October 22, 2026)
- 52-week range: TWD 73.80-188.00 (as of October 22, 2026)
- Sector / Industry: Health Care / Biotechnology
Market context: Market report TAIEX.
More news and analyses on Caliway Biopharmaceuticals C stock
